The Progressive MS Alliance Industry Forum describes a new approach to address barriers to developing treatments for progressive multiple sclerosis (MS). This innovative model promises to facilitate robust collaboration between industry, academia, and patient organizations and accelerate research towards the overarching goal of developing safe and effective treatments for progressive MS
Using the term of progressive multiple sclerosis (PMS), we considered a combined population of perso...
The Author(s) 2012. This article is published with open access at Springerlink.com Abstract The ‘‘MS...
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that causes si...
The Progressive MS Alliance Industry Forum describes a new approach to address barriers to developin...
The Progressive MS Alliance Industry Forum describes a new approach to address barriers to developin...
Therapies for infiltrative inflammation in multiple sclerosis (MS) have advanced greatly, but neurod...
Progressive multiple sclerosis (MS) will be a major area of research interest for years to come. No ...
Despite significant progress in the development of therapies for relapsing MS, progressive MS remain...
Background: People with multiple sclerosis (MS) experience myriad symptoms that negatively affect th...
Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent...
The failure of a majority of clinical trials in progressive multiple sclerosis (MS) has highlighted ...
Multiple sclerosis (MS) is a chronic inflammatory condition of the central nervous system with heter...
The "MS in the 21st Century" initiative was established with the purpose of (1) defining how multipl...
My PhD thesis focuses on two facets of therapeutic strategies to promote neuroprotection and neurore...
Sixteen years ago, there were no licensed treatments for multiple sclerosis (MS). Today, there are s...
Using the term of progressive multiple sclerosis (PMS), we considered a combined population of perso...
The Author(s) 2012. This article is published with open access at Springerlink.com Abstract The ‘‘MS...
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that causes si...
The Progressive MS Alliance Industry Forum describes a new approach to address barriers to developin...
The Progressive MS Alliance Industry Forum describes a new approach to address barriers to developin...
Therapies for infiltrative inflammation in multiple sclerosis (MS) have advanced greatly, but neurod...
Progressive multiple sclerosis (MS) will be a major area of research interest for years to come. No ...
Despite significant progress in the development of therapies for relapsing MS, progressive MS remain...
Background: People with multiple sclerosis (MS) experience myriad symptoms that negatively affect th...
Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent...
The failure of a majority of clinical trials in progressive multiple sclerosis (MS) has highlighted ...
Multiple sclerosis (MS) is a chronic inflammatory condition of the central nervous system with heter...
The "MS in the 21st Century" initiative was established with the purpose of (1) defining how multipl...
My PhD thesis focuses on two facets of therapeutic strategies to promote neuroprotection and neurore...
Sixteen years ago, there were no licensed treatments for multiple sclerosis (MS). Today, there are s...
Using the term of progressive multiple sclerosis (PMS), we considered a combined population of perso...
The Author(s) 2012. This article is published with open access at Springerlink.com Abstract The ‘‘MS...
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that causes si...